<?xml version='1.0' encoding='utf-8'?>
<document id="20100816"><sentence text="Bioactivation of a novel 2-methylindole-containing dual chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells/D-prostanoid receptor antagonist leads to mechanism-based CYP3A inactivation: glutathione adduct characterization and prediction of in vivo drug-drug interaction."><entity charOffset="214-225" id="DDI-PubMed.20100816.s1.e0" text="glutathione" /></sentence><sentence text="The 2-methyl substituted indole, 2MI [2-(4-(4-(2,4-dichlorophenylsulfonamido)-2-methyl-1H-indol-5-yloxy)-3-methoxyphenyl)acetic acid] is a potent dual inhibitor of 1) chemoattractant receptor-homologous molecule expressed on T-helper type-2 cells and 2) d-prostanoid receptor"><entity charOffset="4-31" id="DDI-PubMed.20100816.s2.e0" text="2-methyl substituted indole" /><entity charOffset="33-133" id="DDI-PubMed.20100816.s2.e1" text="2MI [2-(4-(4-(2,4-dichlorophenylsulfonamido)-2-methyl-1H-indol-5-yloxy)-3-methoxyphenyl)acetic acid]" /><pair ddi="false" e1="DDI-PubMed.20100816.s2.e0" e2="DDI-PubMed.20100816.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20100816.s2.e0" e2="DDI-PubMed.20100816.s2.e1" /></sentence><sentence text=" During evaluation as a potential treatment for asthma and allergic rhinitis, 2MI was identified as a mechanism-based inactivator of CYP3A4 in vitro" /><sentence text=" The inactivation was shown to be irreversible by dialysis and accompanied by an NADPH-dependent increase in 2MI covalent binding to a 55- to 60-kDa microsomal protein, consistent with irreversible binding to CYP3A4" /><sentence text=" Two glutathione (GSH) adducts, G1 and G2, were identified in vitro, and the more abundant adduct (G1) was unambiguously determined via NMR to be GSH adducted to the 3-position of the 2-methylindole moiety"><entity charOffset="5-16" id="DDI-PubMed.20100816.s5.e0" text="glutathione" /><entity charOffset="18-21" id="DDI-PubMed.20100816.s5.e1" text="GSH" /><entity charOffset="184-198" id="DDI-PubMed.20100816.s5.e2" text="2-methylindole" /><entity charOffset="146-159" id="DDI-PubMed.20100816.s5.e3" text="GSH" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e0" e2="DDI-PubMed.20100816.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e0" e2="DDI-PubMed.20100816.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e0" e2="DDI-PubMed.20100816.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e0" e2="DDI-PubMed.20100816.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e1" e2="DDI-PubMed.20100816.s5.e1" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e1" e2="DDI-PubMed.20100816.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e1" e2="DDI-PubMed.20100816.s5.e2" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e3" e2="DDI-PubMed.20100816.s5.e3" /><pair ddi="false" e1="DDI-PubMed.20100816.s5.e3" e2="DDI-PubMed.20100816.s5.e2" /></sentence><sentence text=" The potential for a clinical drug-drug interaction arising from mechanism-based inactivation of CYP3A4 by 2MI was predicted using a steady-state model, and a 4" /><sentence text="3- to 7" /><sentence text="5-fold increase in the exposure of midazolam was predicted at anticipated therapeutic concentrations"><entity charOffset="35-44" id="DDI-PubMed.20100816.s8.e0" text="midazolam" /></sentence><sentence text=" To better assess the potential for in vivo drug-drug interactions, the Sprague-Dawley rat was used as an in vivo model" /><sentence text=" An excellent in vitro-in vivo correlation was observed for the reduction in enzyme steady-state concentration (E'(ss/Ess)) as well as the change in the exposure of a prototypical CYP3A substrate, indinavir (area under the curve (AUC) for indinavir/AUC)"><entity charOffset="197-206" id="DDI-PubMed.20100816.s10.e0" text="indinavir" /></sentence><sentence text=" In summary, 2MI was identified as a potent mechanism-based inactivator of CYP3A and was predicted to elicit a clinically relevant drug-drug interaction in humans at an anticipated therapeutic concentration" /><sentence text="" /></document>